Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) EBITDA: 2020-2023

Historic EBITDA for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$30.7 million.

  • Therapeutics' EBITDA fell 36.09% to -$30.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$116.7 million, marking a year-over-year decrease of 39.46%. This contributed to the annual value of -$116.7 million for FY2023, which is 39.46% down from last year.
  • Latest data reveals that Therapeutics reported EBITDA of -$30.7 million as of Q4 2023, which was up 2.11% from -$31.3 million recorded in Q3 2023.
  • Therapeutics' EBITDA's 5-year high stood at -$12.2 million during Q2 2020, with a 5-year trough of -$31.3 million in Q3 2023.
  • Its 3-year average for EBITDA is -$22.5 million, with a median of -$21.2 million in 2022.
  • Data for Therapeutics' EBITDA shows a maximum YoY tumbled of 49.51% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Therapeutics' EBITDA stood at -$13.0 million in 2020, then plummeted by 40.00% to -$18.2 million in 2021, then decreased by 23.89% to -$22.5 million in 2022, then slumped by 36.09% to -$30.7 million in 2023.
  • Its last three reported values are -$30.7 million in Q4 2023, -$31.3 million for Q3 2023, and -$25.8 million during Q2 2023.